PERTH-BASED nano-technology company pSivida Limited has announced that its UK manufacturing partner, Atomising Systems Limited, has completed construction of a dedicated clean-room facility at its Sheffield plant in the UK.
According to pSivida the facility represents a key milestone on the road to manufacturing its BrachySil lead product.
The company added that the development would enable larger clinical trials for advanced liver cancer and future commercialisation of other microparticles crucial to the BrachySil development.
BrachySil has recently shown excellent results in phase II clinical trials as a radiotherapy for the treatment of inoperable primary liver cancer, where it is delivered directly into tumours without surgery in a procedure known as brachytherapy, according to pSivida.
The brachytherapy market is currently valued at more than $US600 million annually and is expected to exceed $US1 billion within the next few years, according to US market research company BioTech Systems.
pSivida believes BrachySil also has the potential to significantly expand the current market size through its application to other cancers.
© Business News 2017. You may share content using the tools provided but do not copy and redistribute.